AstraZeneca AZN is one of the leading drugmakers in the oncology space. Oncology sales (comprising around 41% of AstraZeneca‘s total revenues) rose 13% in the first quarter of 2025, generating $5.6 ...

Modella AI has signed a multi-year agreement with AstraZeneca for expediting AI-driven oncology clinical development.

Bengaluru: AstraZeneca is reportedly in discussions with Summit Therapeutics to license an experimental lung cancer drug in a ...

AstraZeneca and Daiichi Sankyo's TROP2-directed antibody-drug conjugate (ADC) Datroway has been granted accelerated approval from the FDA for a lung cancer indication, seven months after ...

TIGIT-targeting therapies have largely disappointed in recent months, with failed studies, terminated partnerships and ...

AstraZeneca has a target of $5 billion or more in peak annual sales for both Enhertu and Datroway, making the pair a core part of its objective of achieving $80 billion in group revenues by 2030.

Precision oncology has entered a new phase, as data sets mature and a new wave of tools emerges to help clinicians manage ...

The FDA has granted accelerated approval to Datroway for adults with previously-treated, locally advanced or metastatic EGFR-mutated NSCLC.

Global News Select Jul 1, 2025, 9:04:00 AM DATROWAY® approved in the US for patients with previously treated advanced EGFR-mutated non-small cell lung cancer Business Wire Jun 24, 2025, 4:00:00 AM ...

DATROWAY® approved in the US for patients with previously treated advanced EGFR-mutated non-small cell lung cancer Business Wire Jun 24, 2025, 4:00:00 AM ...